A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-05-16

AUTHORS

Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn

ABSTRACT

Background and ObjectivesAnti-tumor necrosis factor alpha (anti-TNFα) therapy is key to the treatment of inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD). The objective of this study was to investigate prescribing patterns and non-persistence of anti-TNFα therapy for the treatment of IBD in a real-world scenario.MethodsData from the Korean National Health Insurance claims database obtained between 2010 and 2014 were evaluated to identify patients with IBD who had received anti-TNFα therapy (infliximab or adalimumab). Patient characteristics and prescribing patterns were investigated. The non-persistence rate and associated reasons were determined in patients who initiated therapy between 2010 and 2012.ResultsA total of 131,158 patients with UC and 57,286 with CD were identified. Of these 1747 UC (1.3%) and 3731 (6.5%) CD patients had received anti-TNFα therapy and were included in the analysis. Infliximab was prescribed more frequently than adalimumab (84.6% vs 15.4% in UC and 80.7% vs 19.4% in CD); 81.0% of UC and 72.0% of CD patients received anti-TNFα alone or in combination with 5-aminosalicylic acid. The non-persistence rate of anti-TNFα therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively).ConclusionThe use of anti-TNFα therapy was seen to be low, with a high rate of non-persistence. Further research efforts are required to improve the response rate and, therefore, improve persistence in patients with IBD. More... »

PAGES

625-630

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-019-00784-7

DOI

http://dx.doi.org/10.1007/s40261-019-00784-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1114500461

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31098835


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Inflammatory Bowel Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "College of Natural Sciences, Andong National University, Andong, Gyeongsangbuk-do, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.252211.7", 
          "name": [
            "College of Natural Sciences, Andong National University, Andong, Gyeongsangbuk-do, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jang", 
        "givenName": "Eun Jin", 
        "id": "sg:person.0750142431.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750142431.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.410886.3", 
          "name": [
            "College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ha", 
        "givenName": "Jung Eun", 
        "id": "sg:person.013611667004.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013611667004.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "College of Natural Sciences, Kyungpook National University, Daegu, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.258803.4", 
          "name": [
            "College of Natural Sciences, Kyungpook National University, Daegu, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Im", 
        "givenName": "Seul Gi", 
        "id": "sg:person.012710111704.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012710111704.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Graduate School of Clinical Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.410886.3", 
          "name": [
            "Graduate School of Clinical Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Myeong Gyu", 
        "id": "sg:person.01141057173.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141057173.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.410886.3", 
          "name": [
            "College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sohn", 
        "givenName": "Hyun Soon", 
        "id": "sg:person.01322617204.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322617204.59"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00535-017-1324-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084022597", 
          "https://doi.org/10.1007/s00535-017-1324-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00535-018-1439-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100940665", 
          "https://doi.org/10.1007/s00535-018-1439-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10620-012-2371-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021922180", 
          "https://doi.org/10.1007/s10620-012-2371-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-05-16", 
    "datePublishedReg": "2019-05-16", 
    "description": "Background and ObjectivesAnti-tumor necrosis factor alpha (anti-TNF\u03b1) therapy is key to the treatment of inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn\u2019s disease (CD). The objective of this study was to investigate prescribing patterns and non-persistence of anti-TNF\u03b1 therapy for the treatment of IBD in a real-world scenario.MethodsData from the Korean National Health Insurance claims database obtained between 2010 and 2014 were evaluated to identify patients with IBD who had received anti-TNF\u03b1 therapy (infliximab or adalimumab). Patient characteristics and prescribing patterns were investigated. The non-persistence rate and associated reasons were determined in patients who initiated therapy between 2010 and 2012.ResultsA total of 131,158 patients with UC and 57,286 with CD were identified. Of these 1747 UC (1.3%) and 3731 (6.5%) CD patients had received anti-TNF\u03b1 therapy and were included in the analysis. Infliximab was prescribed more frequently than adalimumab (84.6% vs 15.4% in UC and 80.7% vs 19.4% in CD); 81.0% of UC and 72.0% of CD patients received anti-TNF\u03b1 alone or in combination with 5-aminosalicylic acid. The non-persistence rate of anti-TNF\u03b1 therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively).ConclusionThe use of anti-TNF\u03b1 therapy was seen to be low, with a high rate of non-persistence. Further research efforts are required to improve the response rate and, therefore, improve persistence in patients with IBD.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40261-019-00784-7", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "keywords": [
      "anti-TNF\u03b1 therapy", 
      "inflammatory bowel disease", 
      "non-persistence rates", 
      "ulcerative colitis", 
      "Crohn's disease", 
      "prescribing patterns", 
      "CD patients", 
      "bowel disease", 
      "CD group", 
      "treatment of IBD", 
      "necrosis factor alpha therapy", 
      "Korean National Health Insurance", 
      "discontinuation of medication", 
      "real-world analysis", 
      "National Health Insurance", 
      "patient characteristics", 
      "alpha therapy", 
      "common reason", 
      "patients", 
      "response rate", 
      "therapy", 
      "disease", 
      "health insurance", 
      "high rate", 
      "treatment", 
      "colitis", 
      "infliximab", 
      "adalimumab", 
      "discontinuation", 
      "medications", 
      "group", 
      "MethodsData", 
      "further research efforts", 
      "rate", 
      "total", 
      "patterns", 
      "insurance", 
      "database", 
      "study", 
      "background", 
      "reasons", 
      "persistence", 
      "analysis", 
      "research efforts", 
      "acid", 
      "objective", 
      "use", 
      "combination", 
      "characteristics", 
      "efforts", 
      "scenarios", 
      "real-world scenarios"
    ], 
    "name": "A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNF\u03b1 Therapy for Inflammatory Bowel Disease", 
    "pagination": "625-630", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1114500461"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-019-00784-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31098835"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-019-00784-7", 
      "https://app.dimensions.ai/details/publication/pub.1114500461"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_834.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40261-019-00784-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00784-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00784-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00784-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00784-7'


 

This table displays all metadata directly associated to this object as RDF triples.

193 TRIPLES      21 PREDICATES      88 URIs      77 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-019-00784-7 schema:about N03a18215770b4f679065619fce563aee
2 N0bda005af4dc4d20998c11142d199e8f
3 N10c9183901e64d0ca1f391c20153dcb0
4 N3ffcc525d4974622a839f5a2572ef31d
5 N4284402163c04ce3920442296df8461f
6 N72b4b2ae4c6241318174c5c606c1b0b2
7 Nc70f71d38c9747f4ac3be8babe796560
8 Nd4fa59c15eef476fac58452f2b0f42d5
9 anzsrc-for:11
10 anzsrc-for:1107
11 schema:author N980930ce044a4c12973c754ab1d7782d
12 schema:citation sg:pub.10.1007/s00535-017-1324-3
13 sg:pub.10.1007/s00535-018-1439-1
14 sg:pub.10.1007/s10620-012-2371-5
15 schema:datePublished 2019-05-16
16 schema:datePublishedReg 2019-05-16
17 schema:description Background and ObjectivesAnti-tumor necrosis factor alpha (anti-TNFα) therapy is key to the treatment of inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD). The objective of this study was to investigate prescribing patterns and non-persistence of anti-TNFα therapy for the treatment of IBD in a real-world scenario.MethodsData from the Korean National Health Insurance claims database obtained between 2010 and 2014 were evaluated to identify patients with IBD who had received anti-TNFα therapy (infliximab or adalimumab). Patient characteristics and prescribing patterns were investigated. The non-persistence rate and associated reasons were determined in patients who initiated therapy between 2010 and 2012.ResultsA total of 131,158 patients with UC and 57,286 with CD were identified. Of these 1747 UC (1.3%) and 3731 (6.5%) CD patients had received anti-TNFα therapy and were included in the analysis. Infliximab was prescribed more frequently than adalimumab (84.6% vs 15.4% in UC and 80.7% vs 19.4% in CD); 81.0% of UC and 72.0% of CD patients received anti-TNFα alone or in combination with 5-aminosalicylic acid. The non-persistence rate of anti-TNFα therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively).ConclusionThe use of anti-TNFα therapy was seen to be low, with a high rate of non-persistence. Further research efforts are required to improve the response rate and, therefore, improve persistence in patients with IBD.
18 schema:genre article
19 schema:isAccessibleForFree false
20 schema:isPartOf N0a0a53db64724a7698cd027272f96c4a
21 N9a12b9ab60d1480c95d62a7fb2c0d174
22 sg:journal.1100199
23 schema:keywords CD group
24 CD patients
25 Crohn's disease
26 Korean National Health Insurance
27 MethodsData
28 National Health Insurance
29 acid
30 adalimumab
31 alpha therapy
32 analysis
33 anti-TNFα therapy
34 background
35 bowel disease
36 characteristics
37 colitis
38 combination
39 common reason
40 database
41 discontinuation
42 discontinuation of medication
43 disease
44 efforts
45 further research efforts
46 group
47 health insurance
48 high rate
49 inflammatory bowel disease
50 infliximab
51 insurance
52 medications
53 necrosis factor alpha therapy
54 non-persistence rates
55 objective
56 patient characteristics
57 patients
58 patterns
59 persistence
60 prescribing patterns
61 rate
62 real-world analysis
63 real-world scenarios
64 reasons
65 research efforts
66 response rate
67 scenarios
68 study
69 therapy
70 total
71 treatment
72 treatment of IBD
73 ulcerative colitis
74 use
75 schema:name A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
76 schema:pagination 625-630
77 schema:productId N0d80fedfa61a44e49039da241214df29
78 N49661e8fe43f4c9898c1c20cd91cbd08
79 Nd052e3c34bc1448bbf1e96ae1b76e835
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1114500461
81 https://doi.org/10.1007/s40261-019-00784-7
82 schema:sdDatePublished 2022-10-01T06:46
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N2c22292faecc4c7e8aab66d32d28600c
85 schema:url https://doi.org/10.1007/s40261-019-00784-7
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N03a18215770b4f679065619fce563aee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Inflammatory Bowel Diseases
91 rdf:type schema:DefinedTerm
92 N0a0a53db64724a7698cd027272f96c4a schema:volumeNumber 39
93 rdf:type schema:PublicationVolume
94 N0bda005af4dc4d20998c11142d199e8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Middle Aged
96 rdf:type schema:DefinedTerm
97 N0d80fedfa61a44e49039da241214df29 schema:name dimensions_id
98 schema:value pub.1114500461
99 rdf:type schema:PropertyValue
100 N0dfa31c876ee48d0bd774db8ee3980c2 rdf:first sg:person.01141057173.78
101 rdf:rest Nec617d089dc54923986b098075f30597
102 N10c9183901e64d0ca1f391c20153dcb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Adult
104 rdf:type schema:DefinedTerm
105 N2c22292faecc4c7e8aab66d32d28600c schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N3ffcc525d4974622a839f5a2572ef31d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Male
109 rdf:type schema:DefinedTerm
110 N4284402163c04ce3920442296df8461f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Adolescent
112 rdf:type schema:DefinedTerm
113 N49661e8fe43f4c9898c1c20cd91cbd08 schema:name doi
114 schema:value 10.1007/s40261-019-00784-7
115 rdf:type schema:PropertyValue
116 N72b4b2ae4c6241318174c5c606c1b0b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N980930ce044a4c12973c754ab1d7782d rdf:first sg:person.0750142431.78
120 rdf:rest Nea8f3fe51e2541a094cf0fbf73e12556
121 N9a12b9ab60d1480c95d62a7fb2c0d174 schema:issueNumber 7
122 rdf:type schema:PublicationIssue
123 Nc70f71d38c9747f4ac3be8babe796560 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 Nd052e3c34bc1448bbf1e96ae1b76e835 schema:name pubmed_id
127 schema:value 31098835
128 rdf:type schema:PropertyValue
129 Nd4fa59c15eef476fac58452f2b0f42d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Tumor Necrosis Factor-alpha
131 rdf:type schema:DefinedTerm
132 Nea8f3fe51e2541a094cf0fbf73e12556 rdf:first sg:person.013611667004.42
133 rdf:rest Nf3372f92e4074d488e3e4e42ddfe0ccc
134 Nec617d089dc54923986b098075f30597 rdf:first sg:person.01322617204.59
135 rdf:rest rdf:nil
136 Nf3372f92e4074d488e3e4e42ddfe0ccc rdf:first sg:person.012710111704.09
137 rdf:rest N0dfa31c876ee48d0bd774db8ee3980c2
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
142 schema:name Immunology
143 rdf:type schema:DefinedTerm
144 sg:journal.1100199 schema:issn 1173-2563
145 1179-1918
146 schema:name Clinical Drug Investigation
147 schema:publisher Springer Nature
148 rdf:type schema:Periodical
149 sg:person.01141057173.78 schema:affiliation grid-institutes:grid.410886.3
150 schema:familyName Kim
151 schema:givenName Myeong Gyu
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141057173.78
153 rdf:type schema:Person
154 sg:person.012710111704.09 schema:affiliation grid-institutes:grid.258803.4
155 schema:familyName Im
156 schema:givenName Seul Gi
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012710111704.09
158 rdf:type schema:Person
159 sg:person.01322617204.59 schema:affiliation grid-institutes:grid.410886.3
160 schema:familyName Sohn
161 schema:givenName Hyun Soon
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322617204.59
163 rdf:type schema:Person
164 sg:person.013611667004.42 schema:affiliation grid-institutes:grid.410886.3
165 schema:familyName Ha
166 schema:givenName Jung Eun
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013611667004.42
168 rdf:type schema:Person
169 sg:person.0750142431.78 schema:affiliation grid-institutes:grid.252211.7
170 schema:familyName Jang
171 schema:givenName Eun Jin
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750142431.78
173 rdf:type schema:Person
174 sg:pub.10.1007/s00535-017-1324-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084022597
175 https://doi.org/10.1007/s00535-017-1324-3
176 rdf:type schema:CreativeWork
177 sg:pub.10.1007/s00535-018-1439-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100940665
178 https://doi.org/10.1007/s00535-018-1439-1
179 rdf:type schema:CreativeWork
180 sg:pub.10.1007/s10620-012-2371-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021922180
181 https://doi.org/10.1007/s10620-012-2371-5
182 rdf:type schema:CreativeWork
183 grid-institutes:grid.252211.7 schema:alternateName College of Natural Sciences, Andong National University, Andong, Gyeongsangbuk-do, South Korea
184 schema:name College of Natural Sciences, Andong National University, Andong, Gyeongsangbuk-do, South Korea
185 rdf:type schema:Organization
186 grid-institutes:grid.258803.4 schema:alternateName College of Natural Sciences, Kyungpook National University, Daegu, South Korea
187 schema:name College of Natural Sciences, Kyungpook National University, Daegu, South Korea
188 rdf:type schema:Organization
189 grid-institutes:grid.410886.3 schema:alternateName College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea
190 Graduate School of Clinical Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea
191 schema:name College of Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea
192 Graduate School of Clinical Pharmacy, CHA University, Pocheon, Gyeonggi-do, South Korea
193 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...